NCT05939674 Effects of Flumazenil on Recovery After Total Intravenous Anesthesia With Remimazolam
| NCT ID | NCT05939674 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Pusan National University Yangsan Hospital |
| Condition | Flumazenil Adverse Reaction |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2023-09-19 |
| Primary Completion | 2026-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2023-09-19 with a primary completion date of 2026-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Remimazolam is a medication that has the advantage of a short half-life and reversibility with flumazenil. In clinical situations, the use of flumazenil for the reversal of sedation is common, but there is no precise indication for its administration. In this study, we aim to investigate the necessity of routine flumazenil use after administering remimazolam for intravenous anesthesia.
Eligibility Criteria
Inclusion Criteria: * Patients over 65 years old scheduled for hip joint surgery Exclusion Criteria: * Patients with impaired consciousness or delirium before surgery * Patients who are hemodynamically unstable before surgery * Patients with a history of neurological or neuromuscular disorders or use of medications that affect neurological or neuromuscular function * Patients who have taken sedatives (anti-anxiety medications, antipsychotics, antidepressants, sleep aids) within the past 24 hours * Patients with known allergy to benzodiazepine, flumazenil * Patients with galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption * Patients with hypersensitivity to Dextran40 * Patients who have been taking benzodiazepine for long term * Patients with end stage renal disease requiring hemodialysis * Patients with history of acute angle glaucoma * Patients with alcohol or substance dependence * ASA classification 4 or 5
Contact & Investigator
Sangwook Shin, MD. PhD
STUDY DIRECTOR
Pusan National University Yangsan Hospital
Frequently Asked Questions
Who can join the NCT05939674 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Flumazenil Adverse Reaction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05939674 currently recruiting?
Yes, NCT05939674 is actively recruiting participants. Contact the research team at wotkdqo@gmail.com for enrollment information.
Where is the NCT05939674 trial being conducted?
This trial is being conducted at Yangsan, South Korea.
Who is sponsoring the NCT05939674 clinical trial?
NCT05939674 is sponsored by Pusan National University Yangsan Hospital. The principal investigator is Sangwook Shin, MD. PhD at Pusan National University Yangsan Hospital. The trial plans to enroll 24 participants.